CRISPR News and Research

Latest CRISPR News and Research

Improved antibody validation

Antibodies are used in a variety of clinical and research situations to examine the structure and function, and distribution of proteins. However, many researchers have found a lack of specificity in the functioning of these antibodies. This means that any work conducted using these antibodies will not yield reliable results.

16 Oct 2019

Study reveals new and surprising function of adenine nucleotide translocator

Mutations in the gene that encodes a protein called adenine nucleotide translocator (ANT) cause a variety of conditions, such as heart disease and weakness of the eye muscles, but the underlying mechanism of how these mutations trigger disease has been unclear.

16 Oct 2019

BioStreamline: Streamlining the development of next generation biotherapeutics

A collaboration to streamline the development of cost-effective next generation biotherapeutics will host a dissemination event at CPI.

From Sphere Fluidics 16 Oct 2019

Oxford Genetics and Sphere Fluidics announce a multi-partner collaboration

Oxford Genetics and Sphere Fluidics announce a multi-partner collaboration to expedite the development of automated microfluidic systems.

From Sphere Fluidics 16 Oct 2019

Researcher explores biological processes that cause fertility problems in humans

With significant funding from the National Institutes of Health (NIH), a researcher at The University of Texas at Arlington is investigating fundamental biological processes that lead to fertility problems in humans.

16 Oct 2019

CRISPR helps find difficult to detect cancer cells

Immunotherapy is one of the latest and most effective armaments against various types of cancers. Some of the immunotherapy drugs such as PD-1 inhibitor Keytruda from Merck can block certain proteins in the cancer cells that can make the cells invisible to the immune system normally. Some of the cancers cells can now develop other ways to disguise themselves from being killed by the immune system.

15 Oct 2019

New cancer treatment developed at Yale

Scientists at Yale have developed a method that assists the immune system in identifying and eliminating cancer cells that may be missed by other forms of immunotherapies.

15 Oct 2019

Study suggesting that CRISPR babies are likely to die early has been retracted

A research paper that sparked concerns about the lifespan of China's first gene-edited babies has been retracted due to technical errors.

15 Oct 2019

New system can help the immune system spot and eliminate tumors

Cancer cells are masters at avoiding detection, but a new system developed by Yale scientists can make them stand out from the crowd and help the immune system spot and eliminate tumors that other forms of immunotherapies might miss, the researchers report Oct. 14 in the journal Nature Immunology.

14 Oct 2019

CRISPR RNA-cutting enzyme programmed to destroy viruses in human cells

Many of the world's most common or deadly human pathogens are RNA-based viruses -- Ebola, Zika and flu, for example -- and most have no FDA-approved treatments.

10 Oct 2019

Carnegie Mellon and Yale win NIH grant to advance gene editing technique

A research team from Carnegie Mellon University and Yale University will advance their innovative, synthetic nucleic acid-based gene editing technique under a new grant from the National Institutes of Health's Somatic Cell Genome Editing Program.

7 Oct 2019

UC Davis researchers awarded $1.5 million NIH grant for CRISPR cancer treatment

What if, instead of killing cancer cells or cells about to become cancerous, you could deliver a repair package and fix them? UC Davis researchers have just been awarded $1.5 million from the National Institutes of Health to start work towards that goal.

3 Oct 2019

Entos Pharmaceuticals signs new collaboration agreement with biopharmaceutical company

Entos Pharmaceuticals Inc. ("Entos" or the "Company"), a healthcare biotechnology company focused on the development of next-generation nucleic acid-based therapies using their Fusogenix drug delivery platform, today announced it has entered into a research, development and collaboration agreement ("Agreement") with a clinical stage biopharmaceutical company ("Partner") focused on the development of novel therapeutic compounds targeting autoimmune and inflammatory diseases.

3 Oct 2019